Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02785744 · ClinicalTrials.gov registry record
Genzyme Osteopenia/Osteoporosis Study
A clinical trial, sponsored by NYU Langone Health.
- Completed
- Registry status
- 76
- Enrollment target
NCT02785744: Completed study, sponsored by NYU Langone Health.
NCT02785744 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 76 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02785744 has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 76 participants
- Enrollment target
Study Summary
Gaucher disease is a most common genetic metabolic disease characterized by low platelet number, liver and spleen enlargement and various forms of bone diseases including low bone mineral density leading to brittle bones. Various treatment options are now available for this disease. The purpose of this research study is to determine the prevalence of Gaucher disease in patients with low bone mineral density as observed by DEXA scan, which is a form of X-Ray of the bone.
Interventions
- OTHER Gaucher disease DNA mutation analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2016-04-01 |
| Est. Completion | 2019-09-01 |
What the finished NCT02785744 record still lists
NCT02785744 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 76 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Gaucher disease DNA mutation analysis is the first listed.
NCT02785744 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02785744 about?
NCT02785744 is a clinical study titled "Genzyme Osteopenia/Osteoporosis Study". Gaucher disease is a most common genetic metabolic disease characterized by low platelet number, liver and spleen enlargement and various forms of bone diseases including low bone mineral density leading to brittle bones. Various treatment options are now available for this disease. The purpose of ...
What is the current status of trial NCT02785744?
This trial is currently completed. The enrollment target is 76 participants. The study started on 2016-04-01. Estimated completion is 2019-09-01.
What interventions are being tested in trial NCT02785744?
The interventions under investigation include: Gaucher disease DNA mutation analysis (OTHER).
Who is sponsoring clinical trial NCT02785744?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI